Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe Disease
- 1 October 2004
- journal article
- case report
- Published by American Academy of Pediatrics (AAP)
- Vol. 114 (4) , e532-e535
- https://doi.org/10.1542/peds.2003-0988-l
Abstract
We report a patient with Pompe disease who developed reversible nephrotic syndrome during prolonged, high-dose, experimental, enzyme replacement therapy with recombinant human acid α-glucosidase (rhGAA). Because of the development of antibodies to rhGAA and concomitant clinical decline, escalating doses of rhGAA were administered as part of an experimental immune tolerance regimen. Histologic evaluation of kidney tissue revealed glomerular deposition of immune complexes containing rhGAA itself, in a pattern of membranous nephropathy. To our knowledge, this is the first reported case of nephrotic syndrome occurring during enzyme replacement therapy. The nephrotic syndrome gradually resolved after the rhGAA dose was decreased, indicating that decreasing the antigenic load can ameliorate glomerular immune complex deposition associated with enzyme replacement in a highly sensitized patient.Keywords
This publication has 18 references indexed in Scilit:
- Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From MilkPediatrics, 2004
- The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the LiteraturePediatrics, 2003
- Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis IThe Lancet, 2003
- Mutation analysis of the acid β-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to algluceraseMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trialGenetics in Medicine, 2001
- Inhibitor Antibodies to Factor VIII and Factor IX: ManagementSeminars in Thrombosis and Hemostasis, 2000
- Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal ModelsMolecular Genetics and Metabolism, 1999
- Anaphylactoid reactions and nephrotic syndrome - a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothersHaemophilia, 1998
- Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher DiseasePublished by American Academy of Pediatrics (AAP) ,1997
- EXPERIMENTAL GLOMERULONEPHRITISThe Journal of Experimental Medicine, 1961